Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Proteinase

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   43881   clinical trials with a EudraCT protocol, of which   7295   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    23 result(s) found for: Proteinase. Displaying page 1 of 2.
    1  2  Next»
    EudraCT Number: 2005-002402-36 Sponsor Protocol Number: IMP 11815/Amend.01/Amend.2 Start Date*: 2006-04-18
    Sponsor Name:Talecris Biotherapeutics
    Full Title: Multi-center, open-label trial to evaluate the safety and tolerability of Alpha-1 MP in subjects with Alpha-1-antitrypsin (α1AT) deficiency. STAMP: Safety and Tolerability of Alpha-1 MP
    Medical condition: Alpha-1 Antitrypsin (AAT) deficiency
    Disease: Version SOC Term Classification Code Term Level
    9 10001806 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: (No results available)
    EudraCT Number: 2005-003459-12 Sponsor Protocol Number: CE1226_4001 Start Date*: 2006-01-30
    Sponsor Name:CSL Behring GmbH
    Full Title: A Randomized, Placebo-Controlled, Double-Blind, Multicenter Phase III/IV Study to compare the Efficacy and Safety of 60 mg/kg body weight of Zemaira® weekly i.v. administration with Placebo weekly ...
    Medical condition: Chronic augmentation and maintenance therapy in individuals with alpha1-proteinase inhibitor (A1-PI) deficiency and clinical evidence of emphysema.
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004850 10001811 Alpha-1 proteinase inhibitor deficiency LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IE (Completed) DE (Completed) FI (Completed) EE (Completed) SE (Completed) CZ (Completed) DK (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2007-007129-38 Sponsor Protocol Number: CE1226_3001 Start Date*: 2008-03-14
    Sponsor Name:CSL Behring GmbH
    Full Title: An open-label, non-controlled, multicenter, multinational Study to evaluate the Efficacy and Safety of Zemaira® administration in Chronic Augmentation and Maintenance Therapy in Subjects with Emphy...
    Medical condition: Chronic augmentation and maintenance therapy in individuals with alpha1-proteinase inhibitor (A1-PI) deficiency and clinical evidence of emphysema.
    Disease: Version SOC Term Classification Code Term Level
    17.0 100000004850 10001811 Alpha-1 proteinase inhibitor deficiency LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IE (Completed) CZ (Completed) DE (Completed) FI (Completed) SE (Completed) EE (Completed) DK (Completed)
    Trial results: View results
    EudraCT Number: 2009-014286-20 Sponsor Protocol Number: AGTC-AAT-002 Start Date*: 2010-12-21
    Sponsor Name:Applied Genetic Technologies Corporation
    Full Title: A Multiple-Site, Phase 2, Safety and Efficacy Trial of a Recombinant Adeno-associated Virus Vector Expressing Alpha 1 Antitrypsin (rAAV1-CB-hAAT) in Patients with Alpha 1 Antitrypsin Deficiency
    Medical condition: Alpha 1 antitrypsin deficiency.This is an inherited, genetic condition characterized by reduced serum levels of alpha-1 antitrypsin (AAT) which increases the risk of developing emphysema and liver ...
    Disease: Version SOC Term Classification Code Term Level
    12.1 10001806 Alpha-1 anti-trypsin deficiency PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IE (Completed)
    Trial results: View results
    EudraCT Number: 2015-001297-18 Sponsor Protocol Number: ALN-AAT-001 Start Date*: 2015-06-29
    Sponsor Name:Alnylam Pharmaceuticals, Inc.
    Full Title: A Phase 1/2, Randomized, Single-Blind, Placebo-Controlled, Single-Ascending, and Multiple-Dose, Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics Study of Subcutaneously Administered ALN...
    Medical condition: ZZ Type Alpha-1 Antitrypsin Deficiency Liver Disease
    Disease: Version SOC Term Classification Code Term Level
    19.1 10010331 - Congenital, familial and genetic disorders 10001806 Alpha-1 anti-trypsin deficiency PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2008-001962-94 Sponsor Protocol Number: EC07/90306 Start Date*: 2008-07-02
    Sponsor Name:Marc Miratvilles
    Full Title: Efecto antiinflamatorio bronquial del tratamiento sustitutivo en pacientes con déficit de alfa-1 antitripsina
    Medical condition: El déficit de alfa-1-antitripsina (AAT) es una enfermedad hereditaria de expresión autosómica recesiva que se caracteriza por concentraciones anormalmente reducidas de AAT en sangre, lo que comport...
    Disease: Version SOC Term Classification Code Term Level
    9 10001806 Alpha-1 anti-trypsin deficiency PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2021-005217-14 Sponsor Protocol Number: DCR-A1AT-202 Start Date*: 2022-03-09
    Sponsor Name:Dicerna Pharmaceuticals, Inc.
    Full Title: A Phase 2 Open-Label Extension Study to Evaluate the Safety and Pharmacodynamics of Belcesiran in Patients with PiZZ Alpha-1 Antitrypsin Deficiency Associated Liver Disease
    Medical condition: PiZZAlpha-1 Antitrypsin Deficiency Associated Liver Disease
    Disease: Version SOC Term Classification Code Term Level
    23.1 100000004850 10001806 Alpha-1 anti-trypsin deficiency LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2008-005326-36 Sponsor Protocol Number: Kamada-AAT(inhaled)-007 Start Date*: 2009-11-02
    Sponsor Name:Kamada Limited
    Full Title: A Phase II/III, Double-Blind, Randomized, Placebo-Controlled, Multicenter, International Study Evaluating the Safety and Efficacy of Inhaled, Human, Alpha-1 Antitrypsin (AAT) in Alpha-1 Antitrypsin...
    Medical condition: Alpha-1 Antitrypsin deficiency in patients with emphysema.
    Disease: Version SOC Term Classification Code Term Level
    17.0 10010331 - Congenital, familial and genetic disorders 10001806 Alpha-1 anti-trypsin deficiency PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) NL (Completed) SE (Completed) DK (Completed) DE (Completed) IE (Completed)
    Trial results: View results
    EudraCT Number: 2007-004869-18 Sponsor Protocol Number: 030547 Start Date*: 2008-07-03
    Sponsor Name:UHB NHS Foundation Trust
    Full Title: Evaluation of the relative severity of pulmonary neutrophilic inflammation and therapeutic modification with IV Prolastin by means of 18 FDG PET/CT scanning in subjects with alpha1-antitrypsin defi...
    Medical condition: The medical condition is emphysema and will be investigated in subjects with alpha 1-antitrypsin deficiency.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10001811 Alpha-1 proteinase inhibitor deficiency LLT
    9.1 10014563 Emphysema pulmonary LLT
    9.1 10010952 COPD LLT
    9.1 10006458 Bronchitis chronic LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2016-000917-59 Sponsor Protocol Number: ARCAAT2001 Start Date*: 2016-06-29
    Sponsor Name:Arrowhead Pharmaceuticals, Inc
    Full Title: An Open-Label, Multi-dose, Phase 2 Study to Determine the Safety, Tolerability and Effect on Circulating and Intrahepatic Alpha-1 Antitrypsin Levels of ARC-AAT as evidenced by changes in liver biop...
    Medical condition: Alpha-1 Antitrypsin Deficiency related liver disease
    Disease: Version SOC Term Classification Code Term Level
    19.1 10010331 - Congenital, familial and genetic disorders 10001806 Alpha-1 anti-trypsin deficiency PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IE (Prematurely Ended) SE (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2020-003313-35 Sponsor Protocol Number: DCR-A1AT-201 Start Date*: 2022-01-18
    Sponsor Name:Dicerna Pharmaceuticals, Inc.
    Full Title: A Phase 2, Randomized, Double-blind, Placebo-controlled Study Investigating Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Two Dose Levels of Belcesiran in Patients with Alpha-1 ...
    Medical condition: PiZZAlpha-1 Antitrypsin Deficiency Associated Liver Disease
    Disease: Version SOC Term Classification Code Term Level
    23.1 100000004850 10001806 Alpha-1 anti-trypsin deficiency LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) SE (Prematurely Ended) NL (Ongoing) PT (Prematurely Ended) BE (Completed) ES (Prematurely Ended) FR (Completed) AT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2019-000068-86 Sponsor Protocol Number: AROAAT2002 Start Date*: 2019-07-01
    Sponsor Name:Arrowhead Pharmaceuticals, Inc.
    Full Title: A Pilot Open Label, Multi-dose, Phase 2 Study to Assess the Safety and Efficacy of ARO-AAT in Patients with Alpha-1 Antitrypsin Deficiency Associated Liver Disease (AATD)
    Medical condition: alpha-1 antitrypsin deficiency (AATD)-associated liver disease
    Disease: Version SOC Term Classification Code Term Level
    23.1 100000004850 10001806 Alpha-1 anti-trypsin deficiency LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) DE (Completed) AT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2018-000768-27 Sponsor Protocol Number: IFX-1-P2.5 Start Date*: 2019-01-10
    Sponsor Name:InflaRx GmbH
    Full Title: A RANDOMIZED, DOUBLE-BLIND, DOUBLE-DUMMY, ACTIVE-CONTROLLED, MULTICENTER, 2-PART PHASE II STUDY ON REPLACEMENT OF STEROIDS BY IFX-1 IN ACTIVE GRANULOMATOSIS WITH POLYANGIITIS (GPA) AND MICROSCOPIC ...
    Medical condition: Active Granulomatosis with Polyangiitis (Wegener’s) (GPA) and Microscopic Polyangiitis (MPA)
    Disease: Version SOC Term Classification Code Term Level
    21.1 10047065 - Vascular disorders 10063344 Microscopic polyangiitis PT
    21.1 10047065 - Vascular disorders 10072579 Granulomatosis with polyangiitis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) DE (Completed) SE (Completed) NL (Completed) IE (Completed) GB (GB - no longer in EU/EEA) ES (Prematurely Ended) DK (Prematurely Ended) BE (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2018-001309-95 Sponsor Protocol Number: MPH966-2-01 Start Date*: 2018-11-30
    Sponsor Name:Mereo BioPharma 4 Ltd
    Full Title: A Phase 2, proof-of-concept, multicentre, double-blind, randomised, dose-ascending, sequential group, placebo-controlled study to evaluate the mechanistic effect, safety, and tolerability of 12 wee...
    Medical condition: Alpha-1 antitrypsin deficiency
    Disease: Version SOC Term Classification Code Term Level
    20.1 10010331 - Congenital, familial and genetic disorders 10001806 Alpha-1 anti-trypsin deficiency PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) SE (Completed) DK (Completed) ES (Ongoing) PL (Completed) BE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2018-003385-14 Sponsor Protocol Number: AROAAT2001 Start Date*: 2019-08-06
    Sponsor Name:Arrowhead Pharmaceuticals, Inc.
    Full Title: A Placebo-Controlled, Multi-dose, Phase 2/3 Study to Determine the Safety, Tolerability and Effect on Liver Histologic Parameters in Response to ARO-AAT in Patients with Alpha-1 Antitrypsin Deficie...
    Medical condition: alpha-1 antitrypsin deficiency (AATD)-associated liver disease
    Disease: Version SOC Term Classification Code Term Level
    23.0 10001806 - Alpha-1 anti-trypsin deficiency 10001806 Alpha-1 anti-trypsin deficiency LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IE (Prematurely Ended) SE (Completed) ES (Restarted) GB (GB - no longer in EU/EEA) PT (Completed) NL (Ongoing) DE (Completed) AT (Completed) IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2009-010335-41 Sponsor Protocol Number: RRK3728 Start Date*: 2009-06-30
    Sponsor Name:University of Birmingham
    Full Title: A MULTICENTRE, PHASE II, OPEN LABEL, RANDOMISED CONTROLLED TRIAL OF REPEATED AUTOLOGOUS INFUSIONS OF G-CSF MOBILISED CD133+ BONE MARROW STEM CELLS IN PATIENTS WITH CIRRHOSIS
    Medical condition: Liver Cirrhosis
    Disease: Version SOC Term Classification Code Term Level
    14.1 10010331 - Congenital, familial and genetic disorders 10001806 Alpha-1 anti-trypsin deficiency PT
    14.1 10019805 - Hepatobiliary disorders 10009211 Cirrhosis liver LLT
    14.1 10019805 - Hepatobiliary disorders 10024667 Liver cirrhosis LLT
    14.1 10019805 - Hepatobiliary disorders 10064844 Compensated cirrhosis LLT
    14.1 10019805 - Hepatobiliary disorders 10019641 Hepatic cirrhosis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2013-001870-38 Sponsor Protocol Number: GTi1201 Start Date*: 2014-01-09
    Sponsor Name:Grifols Therapeutics Inc.
    Full Title: A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Two Dose Regimens (60 mg/kg and 120 mg/kg) of Weekly Intravenous Alphal-Proteinase Inhibitor (Human) in Sub...
    Medical condition: Pulmonary Emphysema due to Alpha-1-Antitrypsin Deficiency
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004855 10014563 Emphysema pulmonary LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Ongoing) IE (Completed) EE (Completed) DK (Ongoing) ES (Completed) FI (Restarted) PL (Ongoing) DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2021-005726-15 Sponsor Protocol Number: 217102 Start Date*: 2022-05-17
    Sponsor Name:GlaxoSmithKline Research & Development Limited
    Full Title: A 52-week, randomized, double-blind, double-dummy, parallel-group, multi-centre, non-inferiority study to investigate the efficacy and safety of depemokimab compared with mepolizumab in adults with...
    Medical condition: Relapsing or refractory Eosinophilic Granulomatosis with Polyangiitis (EGPA) receiving standard of care (SoC) therapy
    Disease: Version SOC Term Classification Code Term Level
    20.0 10021428 - Immune system disorders 10078117 Eosinophilic granulomatosis with polyangiitis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing) DE (Ongoing) IT (Ongoing) PL (Ongoing) HU (Ongoing) PT (Ongoing) NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2011-004569-33 Sponsor Protocol Number: HGS1006-C1100 Start Date*: 2012-12-20
    Sponsor Name:Human Genome Sciences, Inc. (a wholly owned subsidiary of GlaxoSmithKline PLC)
    Full Title: A Phase 3, Multi-Center, Multinational, Randomized, Double-Blind, Study to Evaluate the Efficacy and Safety of Belimumab (HGS1006) in Combination with Azathioprine for the Maintenance of Remission ...
    Medical condition: Wegener’s granulomatosis (WG) Microscopic polyangiitis (MPA) Vasculitis
    Disease: Version SOC Term Classification Code Term Level
    16.1 10047065 - Vascular disorders 10047888 Wegener's granulomatosis LLT
    16.1 10047065 - Vascular disorders 10063344 Microscopic polyangiitis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) DE (Completed) CZ (Completed) BE (Completed) ES (Completed) IE (Completed) SE (Completed) HU (Completed) IT (Prematurely Ended) PL (Completed)
    Trial results: View results
    EudraCT Number: 2021-004706-22 Sponsor Protocol Number: ImlifidARDSe.01 Start Date*: 2023-02-17
    Sponsor Name:Charité - Universitätsmedizin Berlin
    Full Title: Imlifidase in ANCA-associated vasculitis
    Medical condition: Anti-neutrophil cytoplasmic antibody (ANCA) associated vasculitis with severe diffuse alveolar hemorrhage
    Disease: Version SOC Term Classification Code Term Level
    21.1 10047065 - Vascular disorders 10072579 Granulomatosis with polyangiitis PT
    21.1 10047065 - Vascular disorders 10063344 Microscopic polyangiitis PT
    21.1 10038738 - Respiratory, thoracic and mediastinal disorders 10001052 Acute respiratory distress syndrome PT
    21.1 10038738 - Respiratory, thoracic and mediastinal disorders 10037314 Pulmonary alveolar hemorrhage LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Ongoing)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Mon May 20 00:30:36 CEST 2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA